Zevra Therapeutics (NASDAQ: ZVRA) — Perfil da empresa, notícias e dados financeiros
Zevra Therapeutics develops therapies for pain management and aims to address unmet medical needs through innovation.
Zevra Therapeutics
Zevra Therapeutics (NASDAQ:ZVRA) focuses on developing and commercializing a diverse portfolio targeting pain management and related conditions. Engaged in innovation-driven projects, Zevra aims to provide advanced therapeutic solutions to improve the quality of life for patients suffering from chronic and acute conditions. The company's objectives include progressing its pipeline through clinical trials, obtaining regulatory approvals for its candidates, and establishing strategic partnerships to maximize its market presence and impact. With a patient-centric approach, Zevra Therapeutics strives to address unmet medical needs by utilizing cutting-edge research and development to bring novel treatments to market.
Resumo
Operações
Produtos e/ou serviços de Zevra Therapeutics
- Research & Development: Zevra conducts research to identify and develop potential therapies for rare diseases.
- Preclinical Development: Zevra perform laboratory and animal studies to evaluate the safety and efficacy of their drug candidates.
- Clinical Trial Development: Zevra designs and conducts clinical trials to assess the safety and effectiveness of their drug candidates in humans.
- Regulatory Affairs: They manage the regulatory approval process with agencies like the FDA to get their drugs approved for market.
- Manufacturing Partnerships: Zevra might partner with other companies for large-scale manufacturing of their drugs once approved.
- Commercialization Planning: In the future, they might plan for commercialization activities such as marketing and sales of their approved drugs (although they currently don't have any).
equipe executiva do Zevra Therapeutics
- Neil F. McFarlanePresident, CEO & Director
- Rahsaan W. ThompsonChief Legal Officer, Secretary & Compliance Officer
- Justin A. RenzCFO & Treasurer
- Nichol L. OchsnerVice President of Investor Relations & Corporate Communications
- Alison PetersChief People Officer
- Joshua M. SchaferChief Commercial Officer
- Adrian QuartelConsultant
- Tanya HaydenSenior VP & Chief of Staff
- Timothy J. SangiovanniSenior VP of Finance & Corporate Controller
Últimas notícias sobre a Zevra Therapeutics
Principais indicadores financeiros
Resultados divulgados pela Zevra Therapeutics, em USD.
- Cap. de mercado
- 597,1 mi
- Receita (TTM)
- 136,1 mi
- P/L
- 10.9
- LPA (diluído, TTM)
- 0.9
- Dividend yield
- —
- Margem de lucro
- 42.8%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 106,5 mi | -4,2 mi | 83,2 mi | |
| 23,6 mi | -87 mi | -105,5 mi | |
| 27,5 mi | -49,6 mi | -46 mi | |
| 10,2 mi | -42,6 mi | -26,8 mi |